Drug Class Review: TARGETED IMMUNE MODULATORS – UPDATE 3

1. How do included drugs compare in their efficacy and long-term effectiveness for alleviating symptoms and stabilizing the disease in patients with rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, or plaque psoriasis? 2. What are the comparative incidence and severity of harms associated with the use of these drugs? 3. Do the included drugs differ in effectiveness or harms in the following subgroups: ? Different genders, or different racial, age or socioeconomic groups? ? Patients with co-morbidities? ? Patients taking other commonly prescribed drugs? ? Patients with early aggressive vs. persistent rheumatoid arthritis